At WIB-Metro New York’s October 20, 2016, networking meeting held at PRIDE Global Event Space, Valerie Barber Palmieri, CEO of Vermillion, urged all in attendance to pay close attention to changes in our bodies: persistent, unexplained changes may indicate a serious condition.
To illustrate Valerie’s point, patient advocate and ovarian cancer “thriver” Sherry Pollex, who has teamed up with the National Ovarian Cancer Alliance, joined Palmieri on stage and recounted her frightening diagnosis after a harrowing six months of seeking answers to her symptoms.
These symptoms, which can be found in a brochure titled “Ova and Beyond: A Zine Created for Every Woman” from Vermillion, include:
Trouble eating, or feeling full quickly
Abdominal or pelvic pain
Frequent or urgent need to urinate
Upset stomach or heartburn
Constipation or menstrual changes
Pain during intercourse
The brochure authors state that if you experience these symptoms for longer than two weeks, make an appointment with your physician. To learn more about your risk for ovarian cancer, take a quiz to determine where you stand. For information found in the brochure, visit here.
While there is still no cure for ovarian cancer, some advancements have been made in how the disease is diagnosed and treated. Tools and tests like the ones developed at Vermillion include OVA1 and Overa, which are helping physicians more accurately sort pelvic masses.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat, and improve gynecologic health outcomes for women.
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1(R), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March, 2016, Vermillion received FDA clearance for Overa (TM), a second generation OVA1 test with significantly improved specificity and ease of use. For additional information on these products, including published clinical trials, visit here.
Click here for more photos